A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III ( APOC3 ) and, as a result, express half the amount of apoC-III present in noncarriers. Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-cholesterol. Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels,59,60”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, rare heterozygous LOF variants in APOC3 encoding apo C-III are associated with ∼50% reduced TG levels and significantly increased clearance of very-low-density lipoprotein (VLDL).8,9”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Founder populations (such as those from Finland and Iceland) have provided multiple examples of otherwise rare risk alleles driven to higher frequency locally through drift and/or selection49–52.”
From A brief history of human disease genetics (2020) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Cited by
Items 501–600 of 682
Apolipoprotein genetic variants and hereditary amyloidosis
Jeraj, N., Hegele, R. A., & Berberich, A. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000736 · Cited by 8
“Apo C-III deficiency has been described in a few kindreds, with heterozygous loss of function carriers showing lower fasting and postprandial triglyceride levels, higher HDL cholesterol, and, in some, lower levels of LDL cholesterol [41].”
BackgroundNovel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 8
Genetics of Subclinical Coronary Atherosclerosis
Bielak, L. F., & Peyser, P. A. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0145-x · Cited by 8
Self-citationYu, J., Wang, H., Yang, S.-M., Yuan, J., Chen, L., Chen, C. L., Huang, D. F., Wang, Y., Ju, S.-Q., & ZHU, J.-Y. (2009) · Laboratory Medicine · doi:10.1309/lmubypdivgqwoy2u · Cited by 7
Reyes-Soffer, G., Liu, J., Thomas, T., Matveyenko, A., Seid, H., Ramakrishnan, R., Holleran, S., Zaghloul, N., Sztalryd-Woodle, C., Pollin, T., et al. (2023) · doi:10.1101/2023.06.23.23291823 · Cited by 6
Self-citationTian, Z., Luo, H., Chu, Y., Liu, Y., Gao, S., Song, L., Yang, Z., & Liu, D. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01513-4 · Cited by 6
“Thus, mutations in APOC3 lead to cardioprotective effects through TG reduction [16, 17].”
Apolipoproteins in circulation: At the interface of thrombosis and stroke initiation
Etuzé, T., Vivien, D., & Dubois, F. (2025) · Progress in Lipid Research · doi:10.1016/j.plipres.2025.101343 · Cited by 7
Ancestral diversity in complex disease genetics: from discovery to translation
Kuchenbaecker, K. B., & Navoly, G. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00921-3 · Cited by 9
Human genetic variation determines 24-hour rhythmic gene expression and disease risk
Chen, Y., Liu, P., Sabo, A., & Guan, D. (2025) · Nature Communications · doi:10.1038/s41467-025-59524-5 · Cited by 11
Life is complicated: so is apoCIII
Reyes‐Soffer, G., & Ginsberg, H. N. (2019) · Journal of Lipid Research · doi:10.1194/jlr.c119000214 · Cited by 6
Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
Recio-López, P., Valladolid‐Acebes, I., Hadwiger, P., Hoßbach, M., Krampert, M., Prata, C. A. H., Berggren, P., & Juntti‐Berggren, L. (2022) · BioFactors · doi:10.1002/biof.1885 · Cited by 6
Kim, D. H., Lee, S., Noh, S. G., Lee, J., & Chung, H. Y. (2024) · Aging · doi:10.18632/aging.205610 · Cited by 9
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Zeggini, E., Gloyn, A. L., & Hansen, T. F. (2016) · Diabetologia · doi:10.1007/s00125-016-3926-3 · Cited by 6
“have a similar protective association with lipid levels in the Old Order Amish, an independent founder population [8].”
BackgroundVerbeek, R., Oldoni, F., Surendran, R. P., Zwinderman, A. H., Khaw, K., Stroes, E. S. G., Wareham, N. J., Boekholdt, S. M., & Dallinga‐Thie, G. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.02.005 · Cited by 7
Wang, M., Zhou, Y., He, X., Deng, C., Liu, X., Li, J., Zhou, L., Li, Y., Zhang, Y., Liu, H., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.07.022 · Cited by 6
Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis
Xian, X., Wang, Y., & Liu, G. E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_26 · Cited by 7
Dedousis, N. L., Teng, L., Kanshana, J. S., & Kohan, A. B. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100284 · Cited by 7
Gillum, D. R., & Staffileno, B. A. (2011) · Journal of Transcultural Nursing · doi:10.1177/1043659610395772 · Cited by 6
“A follow-up study (Pollin et al., 2008) identified that a deficiency of APOC3, which normally inhibits triglyceride hydrolysis, had been found in 5% of the Lancaster Amish.”
BackgroundTriglycerides and Cardiovascular Disease : A Scientific Statement From the
Pennathur, S., Kris‐Etherton, P. M., Lennie, T. A., Levi, M., Mazzone, T., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Stone, N. J., Ballantyne, C. M., et al. (2011) · Cited by 6
Assessing Rare Variation in Complex Traits
Kuchenbaecker, K. B., & Appel, E. V. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7868-7_5 · Cited by 7
Victor A. McKusick and Medical Genetics Among the Amish
Francomano, C. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1677-7_13 · Cited by 7
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 6
Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers
Wang, F., You, D., Niu, X., Shi, J. G., Li, Y., Qi, L., & Li, H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02929-9 · Cited by 6
Cabodevilla, A. G., Izquierdo, M. C., Basu, D., Younis, W., Tirumalasetty, M. B., Miao, Q. R., Nasias, D., Kanter, J. E., Ho, T. W. W., Gjini, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68193-3 · Cited by 6
“Othergenes that regulate TG metabolism such as the LpL inhibitors angiopoietin-like protein 3 and 4 (ANGPTL3, ANGPTL4) 57,58 , apolipoprotein C-3 (APOC3) and apolipoprotein A-5 (APOA5) are also linked to the risk of CVD 59,60 .”
Björnson, E., Packard, C. J., & Borén, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109010 · Cited by 6
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource
Koch, C., Khalid, S., Khan, M. Z., Bandyadka, S., Doyon, B., Denning, D. P., Jahanzaib, M., Mian, M. R., Gul, W., Liaqat, M. B., et al. (2026) · Nature · doi:10.1038/s41586-026-10667-5 · Cited by 7
Self-citationJeong, J., Rastogi, A., Kim, T., Henry, S. P., Hoffmaster, C. M., Kim, S. Y., Kim, W., Lee, S.-Y., Park, J., Wi, I.-S., et al. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2024.0057 · Cited by 6
“In addition, body weights were measured on GD 0, 2, 4, 6, 8, 10, 12, 14, 16, and 18 during the gestation period.”
Associations of genome-wide and regional autozygosity with 96 complex traits in old order Amish
Lynch, M. T., Maloney, K. A., Xu, H., Perry, J. A., Shuldiner, A. R., Mitchell, B. D., & Regeneron Genetics Center N/A (2023) · BMC Genomics · doi:10.1186/s12864-023-09208-5 · Cited by 5
Self-citationChukwurah, M. I., & Miller, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01926-2 · Cited by 5
Self-citationO-glycoprofiling of Serum Apolipoprotein C-III in Colorectal Cancer
Kianičková, K., Pakanová, Z., Květoň, F., Holazová, A., Kundalia, P. H., Baráth, P., Miljuš, G., Nedić, O., & Katrlík, J. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2901032 · Cited by 6
“Persons with a rare apoC3 null mutation R19X have much lower concentrations of apoC-III and TG in the circulation, and a cardioprotective phenotype [35].”
BackgroundThe role of protective genetic variants in modulating epigenetic aging
Bejaoui, Y., Srour, L., Qannan, A., Oshima, J., Saad, C., Horvath, S., Mbarek, H., & Hajj, N. E. (2025) · GeroScience · doi:10.1007/s11357-025-01548-2 · Cited by 5
APOC3: Triglycerides do matter
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.38 · Cited by 5
“pathways.(7,8) Carriers of a null mutation (R19X) in APOC3 gene in the genome-wide association study (GWAS) had significantly lower triglyceride levels, higher HDL-C level, and reduced coronary artery calcification compared to non-carriers, suggesting a potential cardioprotective effect for lifelong deficiency of APOC…”
BackgroundInfluentialGenomics of Aerobic Capacity and Endurance Performance: Clinical Implications
Pitsiladis, Y. P., Wang, G., & Wolfarth, B. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-355-8_8 · Cited by 6
Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Missense variants in SORT1 are associated with LDL-C in an Amish population
Mitok, K. A., Schueler, K. L., King, S. M., Orr, J., Ryan, K. A., Keller, M. P., Krauss, R. M., Mitchell, B. D., Shuldiner, A. R., & Attie, A. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100468 · Cited by 5
Self-citationCrawford, D. C., RESTREPO, N. A., Diggins, K. E., Farber‐Eger, E. H., & Wells, Q. S. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0387-1 · Cited by 5
“APOC3 R19X was originally identified in a genome-wide association study (GWAS) of TG levels in the Pennsylvania Amish where a variant in linkage disequilibrium with R19X was significantly associated with decreased TG levels [8].”
BackgroundInfluentialCorbin, L. J., Hughes, D. A., Chetwynd, A. J., Taylor, A. E., Southam, A. D., Jankevics, A., Weber, R. J. M., Groom, A., Dunn, W. B., & Timpson, N. J. (2020) · Metabolomics · doi:10.1007/s11306-020-01689-9 · Cited by 5
Choe, H. J., Park, S. H., Han, K., Moon, M. K., & Koo, B. K. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.11.008 · Cited by 7
Mapping Genes in Isolated Populations: Lessons from the Old Order Amish
Mitchell, B. D., Schäffer, A. A., Pollin, T. I., Streeten, E. A., Horenstein, R. B., Steinle, N., Yerges‐Armstrong, L. M., Shuldiner, A. R., & O’Connell, J. R. (2015) · Springer eBooks · doi:10.1007/978-3-662-46306-2_10 · Cited by 6
Self-citationClinical and genetic validity of quantitative bipolarity
Bruce, H. A., Kochunov, P., Mitchell, B. D., Strauss, K. A., Ament, S. A., Rowland, L. M., Du, X. M., Fisseha, F., Thangavelu, K., Chiappelli, J., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0561-z · Cited by 6
Self-citationBayesian model comparison for rare variant association studiesPreprint
Venkataraman, G. R., DeBoever, C., Tanigawa, Y., Aguirre, M., Ioannidis, A. G., Mostafavi, H., Spencer, C. C. A., Poterba, T., Bustamante, C. D., Daly, M. J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/257162 · Cited by 5
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
“Individuals with genetic loss-of-function mutations in the APOC3 gene exhibit markedly lower TG levels and reduced incidence of CAD, highlighting apoC-III as a compelling therapeutic target for HTG and associated complications [25, 29, 43 ].”
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2414126 · Cited by 4
“In 2008, it was found that 5% of the Lancaster Amish were heterozygous carriers of a null variant in APOC3 , R19X [3].”
Investigating telomere length in progeroid syndromes: implications for aging disorders
Srour, L., Qannan, A., Oshima, J., Mégarbané, A., Bejaoui, Y., & Hajj, N. E. (2025) · Aging · doi:10.18632/aging.206255 · Cited by 4
“Additionally, the presence of a loss-of-function mutation in the PCSK9 gene or the null mutation R19* in APOC3 was related to a low risk of atherosclerosis [16, 17].”
Martín-Campos, J. M. (2021) · Biomedicines · doi:10.3390/biomedicines9111728 · Cited by 4
“Loss-of-function APOC3 variants have been associated with low LDL-c and reduced CVD risk [80,81], but the results of a multi-ethnic study failed to detect any association with low LDL-c [82].”
ResultBian, X., Zhang, Y., Shao, M., Li, J., Ge, J., Li, Z., Peng, H. Y., & Zhang, M. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001361 · Cited by 6
“Moreover, both clinical trials and genetic evidence substantiate the viability of ApoC-III and ANGPTL3 inhibition as potential treatment targets [48,49].”
BackgroundPeng, J., Zhou, B., Xu, T., Hu, X., Zhu, Y., Wang, Y., Pan, S., Li, W., Qian, W., Zong, J., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507265 · Cited by 4
“Decreases TG levels can reduce the CAC Agatston score, a scoring method to estimate and quantify the extent of CAC [37–39].”
MethodPan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2423724 · Cited by 4
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 6
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Koška, J., Hansen, S. L., Hu, Y., Jensen, M., Billheimer, D. D., Nedelkov, D., Budoff, M. J., Allison, M., McClelland, R. L., & Reaven, P. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117584 · Cited by 4
Gillum, D. R., Staffileno, B. A., Schwartz, K., Coke, L. A., & Fogg, L. (2010) · Online Journal of Rural Nursing and Health Care · doi:10.14574/ojrnhc.v10i2.44 · Cited by 5
“In addition, these primary studies have found that lipid levels (Pollin et al., 2008; Pollin et al., 2004, Roberts et al., 2007), prolonged QT intervals (Post, Shen et al.”
BackgroundInvestigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
“associated not only with lower TG levels, but also with higher HDL-C and lower LDL-C levels [89].”
BackgroundIbi, D., Noordam, R., van Klinken, J. B., Li‐Gao, R., de Mutsert, R., Trompet, S., Christen, T., Blauw, L. L., van Heemst, D., Mook‐Kanamori, D. O., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002693 · Cited by 4
Single-cell transcriptomics: an emerging tool in the study of cardiometabolic disease
Khera, A. V., & Mehta, N. N. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0312-0 · Cited by 4
“For example, carriers of the R19X variant at the APOC3 gene, involved in breakdown of circulating fats have substantially decreased postprandial serum triglycerides when assessed after an experimental high-fat challenge [15].”
BackgroundAthyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.958147 · Cited by 5
Davidson, J., & Rotondo, D. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000510 · Cited by 4
“In a genomewide association study, carriers of a rare APOC3 gene knockout variant (R19X) had favourable lipid profiles and reduced rates of atherosclerosis [12].”
BackgroundWalking the VLDL tightrope in cardiometabolic diseases
Kim, M., & Zheng, Z. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.020 · Cited by 4
Farstad-O’Halloran, K., Sooda, A., Iqbal, T., Wilton, S. D., & Aung-Htut, M. T. (2025) · Genes · doi:10.3390/genes16040412 · Cited by 3
“Genetic studies have shown that loss-of-function mutations in the APOC3 gene are associated with significantly lower triglyceride levels, reduced remnant cholesterol, and less coronary artery calcification, a marker of atherosclerosis [5–7].”
Zhou, Z., Chen, J., Wang, H., Han, Y., Liu, C., Shen, Q., Dong, Z., Lu, K., Zhai, C., Xu, Y., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104088 · Cited by 3
“Clinical studies suggest that ApoC3 is a risk factor for VC [23,24].”
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
“…and reduced risks of AP and ASCVD, without apparent adverse phenotypes, supporting a causal role for APOC3 in cardiometabolic risk reduction [17 – 21 Plozasiran is a subcutaneously administered N ‑ acetylgalactosamine (GalNAc) – conjugated siRNA therapeutic designed to selectively reduce hepatic…”
THE STUDY OF LONGEVITY: RECENT UPDATES AND FURTHER DIRECTION. PART 2
Kotovskaya, Y. V., Tkacheva, О. N., Рунихина, Н. К., Kashtanova, D. A., & Boytsov, S. A. (2017) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2017-6-133-138 · Cited by 4
Clinical use of genetic typing in human lipid disorders†
Brown, W. V., Breslow, J. L., & Ballantyne, C. M. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.02.007 · Cited by 3
Han, Y., Qi, R., & Liu, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.147 · Cited by 3
Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
Yang, S., & Moon, Y.-A. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0353-5 · Cited by 3
“Loss-of-function variants of apo-CIII are associated with reduced TG levels and reduced cardiovascular diseases, which makes apoC-III an attractive therapeutic target for hypertriglyceridemia (Jørgensen et al. 2014; Pollin et al. 2008; The TG HDL Working Group of the Exome Sequencing Project, National Heart, Lung, Blo…”
Shou, W., Zhang, C., Shi, J., Wu, H., & Huang, W. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.11.010 · Cited by 3
Andersen, M. K., Grarup, N., Moltke, I., Albrechtsen, A., & Hansen, T. F. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.02.010 · Cited by 3
The forkhead box O family in insulin action and lipid metabolism
Lee, S., Zhu, C., Yamauchi, J., Zhu, P., Feng, X., Qu, S., & Dong, H. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00013-0 · Cited by 4
Wang, X., Ren, S., Yang, X., Masoudi, A., Xue, X., Li, M., Li, H., Zhang, X., Wang, H., & Liu, J. (2021) · The Protein Journal · doi:10.1007/s10930-020-09952-7 · Cited by 3
“It can be seen that the reduction in serum ApoC-III or loss of function can reduce the risk of coronary atherosclerosis [40, 41].”
BackgroundChapter 1 Regulation of Metabolism by Nuclear Hormone Receptors
Huang, H.-J., & Schulman, I. G. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)87001-4 · Cited by 4
Lüscher, T. F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv049 · Cited by 3
“evidence for a causal role for a constituent of a population of triglyceride-rich lipoproteins, apolipoprotein C3 (APOC3), in atherosclerotic vascular disease.(27,28) This provides novel mechanistic insight, since APOC3 inhibits lipoprotein lipase, interferes with the clearance of triglycerides, and limits lipoprotein…”
Pediatric dyslipidemias: lipoprotein metabolism disorders in children
Ballout, R. A., & Remaley, A. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817962-8.00002-0 · Cited by 4
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Rader, D. J., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00001-9 · Cited by 5
Lifestyle Approaches to Lowering Triglycerides
Hankinson, S. J., Miller, M. J., & Freeman, A. M. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_14 · Cited by 2
Self-citationHipertrigliceridemia (> 150 mg/dl) como marcador de riesgo cardiovascular
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500822 · Cited by 4
Whole genome sequence analysis of low-density lipoprotein cholesterol across 246 K individuals
Selvaraj, M. S., Li, X., Li, Z., Buren, E. V., Haidermota, S., Postupaka, D., Hornsby, W., Bis, J. C., Brody, J. A., Cade, B. E., et al. (2025) · Genome biology · doi:10.1186/s13059-025-03698-0 · Cited by 5
“We included age, age2, sex, the first 10 principal components (PC1–10), study groups, and the Mendelian founder lipid variants APOB p.R3527Q and APOC3 p.R19X for the Amish cohort [21, 22] as covariates.”
Self-citationApoC-III inhibition: from regulatory approval to equitable implementation
Gaudet, D., Larouche, M., & Stroes, E. S. G. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01281-z · Cited by 2
Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD
Saum, K. L., Pennathur, S., & Kanter, J. E. (2026) · Circulation Research · doi:10.1161/circresaha.126.327361 · Cited by 3
FNIP1 variants are associated with favourable metabolism in 1 million humans
Hindy, G., Adam, R. C., Sosina, O. A., Pryce, D. S., Blair, D., Herman, J., Lee, J., Dornbos, P., Mayerhofer, E., Gilly, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10864-2 · Cited by 3
Self-citationZhang, W., Yoshiji, S., SLADEK, R. M., Dupuis, J., & Lu, T. (2026) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzag087 · Cited by 2
Thomsen, M. J., Varbo, A., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2014) · Acta bioquímica clínica latinoamericana/Acta bioquímica clínica latinoamericana · Cited by 2
Genetische Analysen als Basis einer individualisierten Medizin bei koronarer Herzkrankheit
Kessler, T., Kaess, B. M., Bourier, F. J., Erdmann, J., & Schunkert, H. (2014) · Herz · doi:10.1007/s00059-013-4048-z · Cited by 2
A Method to Prioritize Quantitative Traits and Individuals for Sequencing in Family-Based Studies
Shah, K. P., & Douglas, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062545 · Cited by 3
“[19] discovered R19X because its tag SNP had an exclusive genome-wide significant association with fasting triglyceride levels.”
BackgroundAssociation of Apolipoprotein C3 Levels and Hepatic Steatosis: A Follow-Up Study
Heinz, P., Boehm, B. O., Schmidberger, J., Kratzer, W., & for the EMIL-Study Group (2020) · Hormone and Metabolic Research · doi:10.1055/a-1116-2333 · Cited by 2
“Moreover, APOC3 was associated with a tendency towards atherothrombosis and an increased risk of cardiovascular disease [18, 19].”
BackgroundGaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
High-Density Lipoprotein Cholesterol and Triglycerides in Coronary Heart Disease Risk Assessment
Miller, M. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00009-8 · Cited by 2
Self-citationThe Liver in Metabolic Syndrome
D’Amore, S., Palasciano, G., & Moschetta, A. (2013) · Springer eBooks · doi:10.1007/978-3-319-01008-3_3 · Cited by 3
Genetic Influences on Blood Lipids and Cardiovascular Disease Risk
Pollin, T. I., Ordovás, J. M., & Guevara‐Cruz, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00026-6 · Cited by 3
Self-citationVariación genética de lipoproteínas y lípidos plasmáticos
Santos, J. L. (2010) · Revista chilena de cardiología · doi:10.4067/s0718-85602010000100009 · Cited by 2
Human apolipoprotein CIII levels; evaluation of three assay methods
Sandin, Å., Olofsson, C., Strålfors, A., Ekberg, N. R., Brismar, K., Juntti‐Berggren, L., & Eggertsen, G. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1725976 · Cited by 2
Cafestol: a multi-faced compound kinetics and metabolic effects of cafestol in mice
van Cruchten, S. T. J. (2010) · doi:10.18174/135163 · Cited by 4
Endogenous and exogenous factors affecting lipoprotein lipase activity
Larsson, M. (2014) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 2
Lipid metabolism: spotlight on modulators of lipoprotein lipase activity
Arndt, L., & Burkhardt, R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000501 · Cited by 2
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2
Yoo, J. H. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e19 · Cited by 2
“Supporting this concept, genetic studies have demonstrated that individuals with loss-of-function mutations in the APOC3 gene display reduced TG levels and lower risk of ASCVD [16].”
Montasser, M. E., Bargal, S. A., Streeten, E. A., Whitlatch, H. B., Yazdi, Z. S., Sirody, J., Kiplagat, R., Beshara, M., O’Connell, J. R., Taylor, S. I., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70594 · Cited by 1
“One example is the APOC3 R19X variant first identified in the Amish as associated with lower triglycerides and subsequently replicated in other populations and was found to offer cardioprotection, ultimately leading to the development of two FDA-approved products targeting APOC3 [34, 48].”
Self-citation
Metadata
- Authors
- Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., Mitchell, B. D., Miller, M., O'Connell, J. R., & Shuldiner, A. R.
- Affiliations
- University of Maryland, Baltimore (US)
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Corresponding author
- Pollin, Toni I.
- ORCID
- Venue
- Science
- Published
- 2008-12-12
- Volume
- 322
- Issue
- 5908
- Pages
- 1702-1705
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2673993
- OpenAlex
- W2061100095
- Semantic Scholar
- d46146fa9f89ec4722b99bade97f6a1d685409c0
- Cited by
- 688
- References
- 34
- Citations by year
- 2026: 31 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 30 · 2021: 41 · 2020: 38 · 2019: 36 · 2018: 52 · 2017: 51 · 2016: 54 · 2015: 49 · 2014: 55 · 2013: 43 · 2012: 23
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01-AG-18728, R01AG018728)
- National Heart, Lung, and Blood Institute (U01HL72515, U01HL084756, U01HL072515, R01HL088119)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR046838)
- National Center for Research Resources (M01RR016500, M01RR000052, M01RR 16500)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, plasma lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, coronary artery calcification, subclinical atherosclerosis, cardioprotection, coronary artery disease, lipolysis
- MeSH terms
- Adult, Cholesterol, Christianity, Coronary Artery Disease, Dietary Fats, Fasting, Female, Haplotypes, Heterozygote, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Pennsylvania, Risk Factors, Triglycerides, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Apolipoprotein C-III, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.